• Je něco špatně v tomto záznamu ?

Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR)

M. Špaček, L. Smolej, M. Šimkovič, L. Nekvindová, Z. Křístková, Y. Brychtová, A. Panovská, S. Mašlejová, L. Bezděková, D. Écsiová, P. Vodárek, J. Zuchnická, J. Mihályová, R. Urbanová, P. Turcsányi, D. Lysák, J. Novák, M. Brejcha, T. Líkařová, P....

. 2023 ; 202 (1) : 40-47. [pub] 20230327

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc23010941

Idelalisib (idela), a phosphatidylinositol 3-kinase inhibitor, and ibrutinib, a Bruton tyrosine kinase inhibitor, were the first oral targeted agents approved for relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). However, no randomised trials of idelalisib plus rituximab (R-idela) versus ibrutinib have been conducted. Therefore, we performed a real-world retrospective analysis of patients with R/R CLL treated with R-idela (n = 171) or ibrutinib (n = 244). The median age was 70 versus 69 years, with a median of two previous lines. There was a trend towards higher tumour protein p53 (TP53) aberrations and complex karyotype in the R-idela group (53% vs. 44%, p = 0.093; 57% vs. 46%, p = 0.083). The median progression-free survival (PFS) was significantly longer with ibrutinib (40.5 vs. 22.0 months; p < 0.001); similarly to overall survival (OS; median 54.4 vs. 37.7 months, p = 0.04). In multivariate analysis, only PFS but not OS remained significantly different between the two agents. The most common reasons for treatment discontinuation included toxicity (R-idela, 39.8%; ibrutinib, 22.5%) and CLL progression (27.5% vs. 11.1%). In conclusion, our data show significantly better efficacy and tolerability of ibrutinib over R-idela in patients with R/R CLL treated in routine practice. The R-idela regimen may still be considered a reasonable option in highly selected patients without a suitable treatment alternative.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23010941
003      
CZ-PrNML
005      
20250114091318.0
007      
ta
008      
230718s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.18736 $2 doi
035    __
$a (PubMed)36971061
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Špaček, Martin $u 1st Department of Medicine - Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Nové Město, Czech Republic $1 https://orcid.org/0000000152508218 $7 xx0063837
245    10
$a Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR) / $c M. Špaček, L. Smolej, M. Šimkovič, L. Nekvindová, Z. Křístková, Y. Brychtová, A. Panovská, S. Mašlejová, L. Bezděková, D. Écsiová, P. Vodárek, J. Zuchnická, J. Mihályová, R. Urbanová, P. Turcsányi, D. Lysák, J. Novák, M. Brejcha, T. Líkařová, P. Vodička, J. Baranová, M. Trněný, M. Doubek, Czech CLL Study Group
520    9_
$a Idelalisib (idela), a phosphatidylinositol 3-kinase inhibitor, and ibrutinib, a Bruton tyrosine kinase inhibitor, were the first oral targeted agents approved for relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). However, no randomised trials of idelalisib plus rituximab (R-idela) versus ibrutinib have been conducted. Therefore, we performed a real-world retrospective analysis of patients with R/R CLL treated with R-idela (n = 171) or ibrutinib (n = 244). The median age was 70 versus 69 years, with a median of two previous lines. There was a trend towards higher tumour protein p53 (TP53) aberrations and complex karyotype in the R-idela group (53% vs. 44%, p = 0.093; 57% vs. 46%, p = 0.083). The median progression-free survival (PFS) was significantly longer with ibrutinib (40.5 vs. 22.0 months; p < 0.001); similarly to overall survival (OS; median 54.4 vs. 37.7 months, p = 0.04). In multivariate analysis, only PFS but not OS remained significantly different between the two agents. The most common reasons for treatment discontinuation included toxicity (R-idela, 39.8%; ibrutinib, 22.5%) and CLL progression (27.5% vs. 11.1%). In conclusion, our data show significantly better efficacy and tolerability of ibrutinib over R-idela in patients with R/R CLL treated in routine practice. The R-idela regimen may still be considered a reasonable option in highly selected patients without a suitable treatment alternative.
650    _2
$a lidé $7 D006801
650    _2
$a senioři $7 D000368
650    _2
$a rituximab $7 D000069283
650    12
$a chronická lymfatická leukemie $7 D015451
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a recidiva $7 D012008
650    _2
$a registrace $7 D012042
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Smolej, Lukáš $u 4th Department of Internal Medicine - Haematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic
700    1_
$a Šimkovič, Martin $u 4th Department of Internal Medicine - Haematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic
700    1_
$a Nekvindová, Lucie $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Křístková, Zlatuše $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Brychtová, Yvona $u Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic
700    1_
$a Panovská, Anna $u Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic
700    1_
$a Mašlejová, Stanislava $u Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic
700    1_
$a Bezděková, Lucie $u Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic
700    1_
$a Écsiová, Dominika $u 4th Department of Internal Medicine - Haematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic
700    1_
$a Vodárek, Pavel $u 4th Department of Internal Medicine - Haematology, University Hospital and Charles University Faculty of Medicine, Hradec Králové, Czech Republic
700    1_
$a Zuchnická, Jana $u Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Mihályová, Jana $u Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic
700    1_
$a Urbanová, Renata $u Department of Haematooncology, University Hospital Olomouc, Olomouc, Czech Republic
700    1_
$a Turcsányi, Peter $u Department of Haematooncology, University Hospital Olomouc, Olomouc, Czech Republic $1 https://orcid.org/0000000308393841
700    1_
$a Lysák, Daniel $u Department of Haematology and Oncology, University Hospital Plzeň, Pilsen, Czech Republic
700    1_
$a Novák, Jan $u Department of Haematology, Third Faculty of Medicine, University Hospital Královské Vinohrady, Praha, Czech Republic
700    1_
$a Brejcha, Martin $u Hospital Agel, Nový Jičín, Czech Republic $7 xx0105595
700    1_
$a Líkařová, Tereza $u 1st Department of Medicine - Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Nové Město, Czech Republic
700    1_
$a Vodička, Prokop $u 1st Department of Medicine - Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Nové Město, Czech Republic $1 https://orcid.org/0000000278481268
700    1_
$a Baranová, Jana $u Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic
700    1_
$a Trněný, Marek $u 1st Department of Medicine - Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Nové Město, Czech Republic
700    1_
$a Doubek, Michael $u Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic
710    2_
$a Czech CLL Study Group
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 202, č. 1 (2023), s. 40-47
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36971061 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230718 $b ABA008
991    __
$a 20250114091314 $b ABA008
999    __
$a ok $b bmc $g 1963389 $s 1197206
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 202 $c 1 $d 40-47 $e 20230327 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
LZP    __
$a Pubmed-20230718

Najít záznam

Citační ukazatele

Možnosti archivace